
3 Tablets and Capsules Exporter, Multi-Speciality Hospitals Chain and Cloud IT Services Provider Stocks With a Strong Future Roadmap: Lincoln Pharmaceuticals, Apollo Hospitals Enterprise and Mphasis
Lincoln Pharmaceuticals, Apollo Hospitals Enterprise and Mphasis: ROE of 11.6% to 20.5% and FY22 to FY26 revenue CAGR of 7.5% to 14.6%. Prices as of 16 Nov 2026.
Updated: 17 Nov 2026 • 3:09 pm
Posted by:

Quick Answer
The three generic tablet, hospital and IT service stocks to watch are Lincoln Pharmaceuticals, Apollo Hospitals Enterprise and Mphasis. Their return on equity ranges from 11.6% to 20.5%, and their revenue compound annual growth from FY22 to FY26 ranges from 7.5% to 14.6%. Apollo Hospitals Enterprise leads on both return on equity at 20.5% and revenue growth at 14.6% a year. Prices are based on the 16 November 2026 close, and this article is educational, not investment advice.
Generic tablet, hospital and IT service stocks offer a focused view of a sector where demand keeps widening. Lincoln Pharmaceuticals, Apollo Hospitals Enterprise and Mphasis cover a pharmaceuticals maker, a hospitals chain and an IT services company.
This list covers three generic tablet, hospital and IT service stocks with complete current figures: Lincoln Pharmaceuticals, Apollo Hospitals Enterprise and Mphasis. Every figure comes from the latest reported financials and the 16 November 2026 market close. Companies without complete current figures were left out.
Click Here – Get Free Investment Predictions
What Are Generic Tablet, Hospital and IT Service Stocks?
Generic tablet, hospital and IT service stocks are listed companies that make tablets, capsules and syrups for India and export markets, run large multi-speciality hospitals and a pharmacy network, and provide IT and cloud services to banks and other global clients. Their earnings depend on medicine orders, patient numbers and client technology budgets.
Generic Tablet, Hospital and IT Service Stocks at a Glance
| Company | CMP (Rs) | Market Cap (Rs Cr) | P/E | Industry P/E | ROE (%) | D/E |
|---|---|---|---|---|---|---|
| Lincoln Pharmaceuticals | 521.15 | 1,067 | 11.1 | 36.0 | 11.6 | 0.01 |
| Apollo Hospitals Enterprise | 8,771 | 110,757 | 51.0 | 59.6 | 20.5 | 0.90 |
| Mphasis | 2,432.9 | 47,695 | 25.0 | 17.5 | 17.3 | 0.24 |
On valuation, Lincoln Pharmaceuticals and Apollo Hospitals Enterprise trade at a P/E below the industry P/E, while Mphasis trades above it, which reflects the growth the market already expects. Readers comparing generic tablet, hospital and IT service stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain. With the Q2 FY27 results season close, investors in generic tablet, hospital and IT service stocks can use the coming numbers to test whether growth is holding.
Why Do Generic Tablet, Hospital and IT Service Stocks Have a Strong Roadmap in India?
Generic tablet, hospital and IT service stocks have a strong roadmap in India because steady demand for medicines, wider access to quality hospital care and rising client spending on cloud work keep widening the market for these companies.
- Pharmaceuticals. Patients need dependable medicines.
- Hospitals. Families seek advanced care.
- IT services. Clients move work to the cloud.
Why Lincoln Pharmaceuticals Features Among These Generic Tablet, Hospital and IT Service Stocks
Among the generic tablet, hospital and IT service stocks on this list, Lincoln Pharmaceuticals is an Ahmedabad-based maker of branded generics and formulations in India and exports to emerging markets, with products across anti-infectives, respiratory and pain care.
Revenue rose from Rs 482 crore in FY22 to Rs 704 crore in FY26, a compound annual growth rate of 9.9%. Net profit grew from Rs 69.4 crore in FY22 to Rs 87.9 crore in FY26, which works out to a compound annual growth rate of 6.1%.
In the June 2026 quarter, revenue grew 19.0% year on year to Rs 202 crore, while net profit rose 30.9% to Rs 36.2 crore. The company has a return on equity of 11.6%, a debt to equity ratio of 0.01 and a market capitalisation of Rs 1,067 crore. The stock trades at a P/E of 11.1, below the industry P/E of 36.0.
Roadmap: The company is expanding its branded portfolio and export markets while adding new products. A focus on emerging markets spreads revenue across regions.
What to watch: Track branded product growth, export orders and new launches.
Why Apollo Hospitals Enterprise Features Among These Generic Tablet, Hospital and IT Service Stocks
Among the pharma exporter, private hospitals and digital services shares on this list, Apollo Hospitals Enterprise is India's largest private healthcare group, running a network of hospitals along with a pharmacy chain, diagnostics, primary care clinics and a digital health platform.
In the June 2026 quarter, revenue grew 20.6% year on year to Rs 7,092 crore, while net profit rose 38.4% to Rs 610 crore. Revenue rose from Rs 14,741 crore in FY22 to Rs 25,420 crore in FY26, a compound annual growth rate of 14.6%.
Net profit grew from Rs 1,101 crore in FY22 to Rs 2,003 crore in FY26, which works out to a compound annual growth rate of 16.1%. The company has a return on equity of 20.5%, a debt to equity ratio of 0.90 and a market capitalisation of Rs 110,757 crore. The stock trades at a P/E of 51.0, below the industry P/E of 59.6.
Roadmap: The company is adding hospital beds in proven cities while growing its pharmacy and digital businesses, which broaden its reach beyond inpatient care. A strong brand in complex treatment and a wide patient base support steady occupancy.
What to watch: Track bed additions and occupancy and the growth of the pharmacy and digital health businesses.
Why Mphasis Features Among These Generic Tablet, Hospital and IT Service Stocks
Among the three companies on this list, Mphasis is a Bengaluru-based IT services company that provides applications, cloud, data and consulting services to clients in banking, insurance and technology, especially in the United States.
The company has a return on equity of 17.3%, a debt to equity ratio of 0.24 and a market capitalisation of Rs 47,695 crore. The stock trades at a P/E of 25.0, above the industry P/E of 17.5.
Revenue rose from Rs 12,122 crore in FY22 to Rs 16,206 crore in FY26, a compound annual growth rate of 7.5%. Net profit grew from Rs 1,431 crore in FY22 to Rs 1,863 crore in FY26, which works out to a compound annual growth rate of 6.8%. In the June 2026 quarter, revenue grew 17.1% year on year to Rs 4,467 crore, while net profit rose 10.8% to Rs 490 crore.
Roadmap: The company has stressed an AI-led approach and strengthened its sales relationships with large clients. A broad client base in financial services provides recurring revenue, and its investments in cloud and data skills support growth.
What to watch: Monitor deal wins and client spending trends in banking and financial services.
Lincoln Pharmaceuticals vs Apollo Hospitals Enterprise vs Mphasis on Key Financials
The table below sets the three generic tablet, hospital and IT service stocks side by side on revenue, profit and margin, using reported figures.
| Company | FY22 Revenue (Rs Cr) | FY26 Revenue (Rs Cr) | Revenue CAGR (FY22-FY26) | FY26 Net Profit (Rs Cr) | FY26 Net Margin |
|---|---|---|---|---|---|
| Lincoln Pharmaceuticals | 482 | 704 | 9.9% | 87.9 | 12.5% |
| Apollo Hospitals Enterprise | 14,741 | 25,420 | 14.6% | 2,003 | 7.9% |
| Mphasis | 12,122 | 16,206 | 7.5% | 1,863 | 11.5% |
Apollo Hospitals Enterprise posts the highest return on equity in this group at 20.5%. Apollo Hospitals Enterprise combines the largest FY26 revenue at Rs 25,420 crore with the fastest revenue growth, a 14.6% compound annual rate. A useful habit with generic tablet, hospital and IT service stocks is to check each new quarterly result against the capacity plans the company described earlier. Many investors spread money across several medicines, tertiary care and IT outsourcing stocks instead of one name, which keeps a single result from deciding the outcome.
The June 2026 quarter, the latest reported, gives a fresh read on momentum:
| Company | Q1 FY26 Revenue (Rs Cr) | Q1 FY27 Revenue (Rs Cr) | Year-on-Year Growth |
|---|---|---|---|
| Lincoln Pharmaceuticals | 169 | 202 | 19.0% |
| Apollo Hospitals Enterprise | 5,882 | 7,092 | 20.6% |
| Mphasis | 3,813 | 4,467 | 17.1% |
Key Risks to Check Before Investing in Generic Tablet, Hospital and IT Service Stocks
Every theme carries risks that deserve a check before any decision. For these generic tablet, hospital and IT service stocks, the main points are: Long-term pharma exporter, private hospitals and digital services shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.
- Regulatory approvals. Plant inspections and approvals can affect supplies.
- Capacity ramp up. New hospitals take time to fill beds and reach full returns.
- Client spending. Technology budgets can vary with global conditions.
Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.
Use the Univest Stock Screener to filter generic tablet, hospital and IT service stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.
Final Thoughts on Generic Tablet, Hospital and IT Service Stocks
Generic tablet, hospital and IT service stocks reward patient research into demand, execution and financial strength. Lincoln Pharmaceuticals, Apollo Hospitals Enterprise and Mphasis each have a clear plan to grow. Based on the 16 November 2026 close, Lincoln Pharmaceuticals trades at Rs 521.15, Apollo Hospitals Enterprise at Rs 8,771 and Mphasis at Rs 2,432.9. Valuation matters as much as growth, so compare each company's P/E with its industry P/E before adding any of these generic tablet, hospital and IT service stocks to a watchlist.
Download the Univest iOS App or Univest Android App to track generic tablet, hospital and IT service stocks, set price alerts and get research-backed stock ideas.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
What are generic tablet, hospital and IT service stocks?
Ans. Generic tablet, hospital and IT service stocks are listed companies that make tablets, capsules and syrups for India and export markets, run large multi-speciality hospitals and a pharmacy network, and provide IT and cloud services to banks and other global clients. Their earnings depend on medicine orders, patient numbers and client technology budgets. This list looks at three of them, Lincoln Pharmaceuticals, Apollo Hospitals Enterprise and Mphasis, using reported FY22 to FY26 financials and the 16 November 2026 closing prices.
Which generic tablet, hospital and IT service stocks are covered in this list?
Ans. This list covers Lincoln Pharmaceuticals, Apollo Hospitals Enterprise and Mphasis. Based on the 16 November 2026 close, Lincoln Pharmaceuticals traded at Rs 521.15, Apollo Hospitals Enterprise at Rs 8,771 and Mphasis at Rs 2,432.9. Their return on equity ranges from 11.6% to 20.5%, and their revenue compound annual growth from FY22 to FY26 ranges from 7.5% to 14.6%.
Why do generic tablet, hospital and IT service stocks have a strong future roadmap in India?
Ans. Generic tablet, hospital and IT service stocks have a strong roadmap in India because steady demand for medicines, wider access to quality hospital care and rising client spending on cloud work keep widening the market for these companies. The main drivers are as follows. Pharmaceuticals. Patients need dependable medicines. Hospitals. Families seek advanced care. IT services. Clients move work to the cloud. Together these factors give the companies on this list a visible path for growth over the coming years.
How has Lincoln Pharmaceuticals performed financially?
Ans. Revenue rose from Rs 482 crore in FY22 to Rs 704 crore in FY26, a compound annual growth rate of 9.9%. Net profit grew from Rs 69.4 crore in FY22 to Rs 87.9 crore in FY26, which works out to a compound annual growth rate of 6.1%. In the June 2026 quarter, revenue grew 19.0% year on year to Rs 202 crore, while net profit rose 30.9% to Rs 36.2 crore. The company has a return on equity of 11.6%, a debt to equity ratio of 0.01 and a market capitalisation of Rs 1,067 crore. The stock trades at a P/E of 11.1, below the industry P/E of 36.0. Looking ahead, the company is expanding its branded portfolio and export markets while adding new products. A focus on emerging markets spreads revenue across regions.
How has Apollo Hospitals Enterprise performed financially?
Ans. Revenue rose from Rs 14,741 crore in FY22 to Rs 25,420 crore in FY26, a compound annual growth rate of 14.6%. Net profit grew from Rs 1,101 crore in FY22 to Rs 2,003 crore in FY26, which works out to a compound annual growth rate of 16.1%. In the June 2026 quarter, revenue grew 20.6% year on year to Rs 7,092 crore, while net profit rose 38.4% to Rs 610 crore. The company has a return on equity of 20.5%, a debt to equity ratio of 0.90 and a market capitalisation of Rs 110,757 crore. The stock trades at a P/E of 51.0, below the industry P/E of 59.6. Looking ahead, the company is adding hospital beds in proven cities while growing its pharmacy and digital businesses, which broaden its reach beyond inpatient care. A strong brand in complex treatment and a wide patient base support steady occupancy.
How has Mphasis performed financially?
Ans. Revenue rose from Rs 12,122 crore in FY22 to Rs 16,206 crore in FY26, a compound annual growth rate of 7.5%. Net profit grew from Rs 1,431 crore in FY22 to Rs 1,863 crore in FY26, which works out to a compound annual growth rate of 6.8%. In the June 2026 quarter, revenue grew 17.1% year on year to Rs 4,467 crore, while net profit rose 10.8% to Rs 490 crore. The company has a return on equity of 17.3%, a debt to equity ratio of 0.24 and a market capitalisation of Rs 47,695 crore. The stock trades at a P/E of 25.0, above the industry P/E of 17.5. Looking ahead, the company has stressed an AI-led approach and strengthened its sales relationships with large clients. A broad client base in financial services provides recurring revenue, and its investments in cloud and data skills support growth.
What risks should investors check before buying generic tablet, hospital and IT service stocks?
Ans. Investors should check a few risks before buying generic tablet, hospital and IT service stocks. Regulatory approvals. Plant inspections and approvals can affect supplies. Capacity ramp up. New hospitals take time to fill beds and reach full returns. Client spending. Technology budgets can vary with global conditions. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.
Is this list of generic tablet, hospital and IT service stocks investment advice?
Ans. No. This article is educational and uses publicly available data as of the 16 November 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.
Recent Articles

High Dividend Yield Stocks in India: Vedanta, Hindustan Zinc, Coal India and CESC Checked on 17 November 2026
17 November 2026

Top Mid-Cap Metal Stocks Compared: Jindal Stainless vs Gravita vs HEG vs Graphite India vs MOIL on Price, Valuation, Q2 FY27 Results and Risks
17 November 2026

Top Mid-Cap Hospital Stocks Compared: Rainbow Children vs HCG vs Jupiter Life Line vs KIMS vs Narayana Hrudayalaya on Price, Valuation, Q2 FY27 Results and Risks
17 November 2026

Top Mid-Cap Capital Goods Stocks Compared: Elgi Equipments vs GMM Pfaudler vs Grindwell Norton vs AIA Engineering vs Cummins India on Price, Valuation, Q2 FY27 Results and Risks
17 November 2026
Note: This blog is for information purpose only. Investments and trading are subject to market risks, read all scheme related documents carefully.
Reviews
Recent Posts
High Dividend Yield Stocks in India: Vedanta, Hindustan Zinc, Coal India and CESC Checked on 17 November 2026
Top Mid-Cap Metal Stocks Compared: Jindal Stainless vs Gravita vs HEG vs Graphite India vs MOIL on Price, Valuation, Q2 FY27 Results and Risks
Top Mid-Cap Hospital Stocks Compared: Rainbow Children vs HCG vs Jupiter Life Line vs KIMS vs Narayana Hrudayalaya on Price, Valuation, Q2 FY27 Results and Risks
Top Mid-Cap Capital Goods Stocks Compared: Elgi Equipments vs GMM Pfaudler vs Grindwell Norton vs AIA Engineering vs Cummins India on Price, Valuation, Q2 FY27 Results and Risks
Top Mid-Cap Auto Stocks Compared: Hyundai Motor India vs Force Motors vs JBM Auto vs Escorts Kubota vs Olectra on Price, Valuation, Q2 FY27 Results and Risks
Popular this week
Top Two-Wheeler Stocks Compared: Hero MotoCorp vs Bajaj Auto vs Eicher Motors vs TVS Motor vs Atul Auto on Price, Valuation, Q2 FY27 Results and Risks

Uniresearch Global Pvt Ltd
Research Analyst
SEBI Registration Number — INH000013776
Uniresearch is a subsidiary of Univest Communication Technologies Private Limited
Company Address: Registered Address: Ground Floor, Unitech Commercial Tower 2, Block B, Greenwood City, Unit 1-3, Sector 45, Gurugram, Haryana 122003
Write to us : support@univest.in, compliance@univest.in
Verify on SEBI registry →RESEARCH ANALYST
Get SEBI Registered
advice on the stocks
trending today.
Get 3 FREE Trade Ideas
for Startups Accelerator 2024
Trusted by 1Cr Indians
Awarded No.1 by Economic Times





